1-Benzoyl-2-hexahydroazepino-ethan | 15391-79-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Benzoyl-2-hexahydroazepino-ethan
• 英文别名: β--propiophenon；3-azepan-1-yl-1-phenyl-propan-1-one；3-(Azepan-1-yl)-1-phenylpropan-1-one
• CAS: 15391-79-4
• 化学式: C₁₅H₂₁NO
• 分子量: 231.338
• InChiKey: GAWIINVGWPHVKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Benzoyl-2-hexahydroazepino-ethan 在 磷化氢 、 乙醚 、 氢碘酸 、 溶剂黄146 、 苯 作用下， 生成 1-(3,3-diphenyl-propyl)-1-methyl-hexahydro-azepinium; iodide
  参考文献：
  名称：

  alpha-alpha-diphenyl-gamma-hexamethyleneiminobutyramide

  摘要：

  公开号：

  US02881165A1
• 作为产物：
  描述：

  环己亚胺 在 盐酸 作用下， 以 乙醇 、 苯 为溶剂， 反应 14.0h， 生成 1-Benzoyl-2-hexahydroazepino-ethan
  参考文献：
  名称：

  Hypolipidemic effects of α, β, and γ-alkylaminophenone analogs in rodents

  摘要：

  A number of N-substituted beta-alkylaminophenone derivatives including two alpha- and two gamma-alkylaminophenone analogs were synthesized and investigated for hypolipidemic activity in mice at 8 mg/kg/day ip. Most of these analogs were found to be significantly more active than lovastatin and clofibrate. N-Phenylpiperazinopropiophenone 16 was one of the best derivatives, lowering serum cholesterol levels 41% and serum triglyceride levels 48% after 16 days of drug administration in CF1 mice. In Sprague-Dawley rats, N-phenylpiperazinopropiophenone at 8 mg/kg/day orally also demonstrated more potent hypolipidemic activity than clofibrate, gemfibrozil, and lovastatin at their therapeutic dosage. It significantly reduced tissue cholesterol and triglyceride levels in the aorta wall tissue and lowered the cholesterol and triglyceride levels in chylomicron, very low density lipid (VLDL) and low density lipid (LDL) fractions, while it significantly elevated the cholesterol levels in high density lipid (HDL) fraction. This compound also proved to be active in lowering both cholesterol and triglyceride levels in hyperlipidemic mice and rats induced with atherogenic diet. In vitro liver acetyl coenzyme A (CoA) synthetase, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase, acyl CoA cholesterol acyl transferase (ACAT), sn-glycerol-3-phosphate acyltransferase, phosphatidylate phosphohydrolase, and hepatic lipoprotein lipase activities were significantly inhibited by N-phenylpiperazinopropiophenone from 25 to 100 mu M.

  DOI：

  10.1016/0223-5234(96)80365-5

文献信息

• Electrooxidative Cyclization of Hydroxyamino Compounds Possessing a Benzyl Group
  作者：Mitsuhiro Okimoto、Kousuke Ohashi、Haruki Yamamori、Shinnosuke Nishikawa、Masayuki Hoshi、Takashi Yoshida

  DOI：10.1055/s-0031-1290755

  日期：2012.5

  3-oxazinane derivatives using only a small excess of base. Several novel 2-aryl-1,3-oxazinane and 2-aryl-1,3-oxazolidine derivatives were synthesized from N-benzyl-2-piperidineethanols and N-benzyl-2-piperidinemethanols, respectively, by using electrooxidative methods in methanol. For these reactions, the yields of the corresponding cyclized compounds were significantly increased by using catalytic amounts

  摘要 通过在甲醇中使用电氧化法，分别从N-苄基-2-哌啶甲醇和N-苄基-2-哌啶甲醇合成了几种新颖的2-芳基-1,3-恶嗪烷和2-芳基-1,3-恶唑烷衍生物。对于这些反应，通过使用催化量的碘离子显着提高了相应环化化合物的产率。相反，3-二烷基氨基-1-苯基丙醇仅使用少量过量的碱即可得到预期的环状6-苯基-1,3-恶嗪烷衍生物。 通过在甲醇中使用电氧化法，分别从N-苄基-2-哌啶甲醇和N-苄基-2-哌啶甲醇合成了几种新颖的2-芳基-1,3-恶嗪烷和2-芳基-1,3-恶唑烷衍生物。对于这些反应，通过使用催化量的碘离子显着提高了相应环化化合物的产率。相反，3-二烷基氨基-1-苯基丙醇仅使用少量过量的碱即可得到预期的环状6-苯基-1,3-恶嗪烷衍生物。
• MASAKI, MITSUO;SHINOZAKI, HARUHIKO;SATOH, MASARU;MORITOH, NAOYA;HASHIMOTO+
  作者：MASAKI, MITSUO、SHINOZAKI, HARUHIKO、SATOH, MASARU、MORITOH, NAOYA、HASHIMOTO+

  DOI：——

  日期：——
• MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：EP2126574B1

  公开（公告）日：2015-12-23
• Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
  申请人：MOCHLY-ROSEN DARIA

  公开号：US20110105602A2

  公开（公告）日：2011-05-05

  The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.
• US9102651B2
  申请人：——

  公开号：US9102651B2

  公开（公告）日：2015-08-11